Cite
HARVARD Citation
Fisher, B. et al. (2020). Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet. pp. e142-e152. [Online].